Review Part 3: Human herpesvirus-6 in multiple non-neurological diseases.

HHV-6 Foundation, Santa Barbara, California, USA.
Journal of Medical Virology (Impact Factor: 2.22). 11/2010; 82(11):1903-10. DOI: 10.1002/jmv.21860
Source: PubMed

ABSTRACT J. Med. Virol. 82:1903–1910, 2010. © 2010 Wiley-Liss, Inc.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Most adults remain chronically infected with HHV-6 after resolution of a primary infection in childhood, with the latent virus held in check by the immune system. latrogenic immunosuppression following solid organ transplantation (SOT) or hematopoetic stem cell transplantation (HSCT) can allow latent viruses to reactivate. HHV-6 reactivation has been associated with increased morbidity, graft rejection, and neurological complications post-transplantation. Recent work has identified HHV-6 antigens that are targeted by the CD4+ and CD8+ T cell response in chronically infected adults. T cell populations recognizing these targets can be expanded in vitro and are being developed for use in autologous immunotherapy to control post-transplantation HHV-6 reaction.
    Current Opinion in Virology 12/2014; 9. DOI:10.1016/j.coviro.2014.10.001 · 6.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The tumor suppressor p53 pathway, whose alterations are highly associated with all types of human cancers, plays an essential role in preventing tumor development and progression mostly through its downstream target genes. Over the last decade, a growing list of p53 microRNA (miRNA) targets has been identified as additional downstream players of this pathway. Further studies of these miRNAs have revealed their more complicated regulations and functions in executing and/or regulating p53 activity. Here, we review the p53 miRNA targets identified thus far, and discuss how they fine-tune p53 stress responses, mediate the crosstalk between p53 and other signaling pathways, and expand the role of p53 in other human diseases in addition to cancers.
    Journal of Molecular Cell Biology 04/2014; DOI:10.1093/jmcb/mju018 · 8.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The triggering agent of multiple sclerosis is still unknown and many viruses, including human herpesvirus-6 (HHV-6), are under suspicion. In earlier study we found patients who had HHV-6 reactive OCBs in their CSF. We wanted to investigate whether HHV-6 has an active role in diseases with demyelination. Objective To analyze the HHV-6-reactive cases in detail and investigate the possible independent role of HHV-6 in the development of central nervous system involvements with demyelination. Study design We studied serum and CSF samples that were collected over a period of one year, from all patients who had oligoclonal bands (OCB) in cerebrospinal fluid (CSF) and were examined in the Department of Neurology, University Central Hospital of Helsinki, Finland. Clinical evaluation was accomplished blinded of HHV-6 analysis and follow-up time was two years. All patients underwent MRI of the head and clinically indicated CSF analysis. Results The 17 patients with HHV-6-reactive OCBs were significantly younger and had significantly more IgG-OCBs in comparison to patients without HHV-6-reactive OCBs. Initial diagnoses in patients with HHV-6-reactive OCBs remained the same during the follow-up time. Conclusion Patients with HHV-6-positive OCBs appear to form a separable group. In progressive neurological diseases HHV-6 may have a role in long-term infection with demyelination.
    Journal of Clinical Virology 10/2014; 61(2). DOI:10.1016/j.jcv.2014.07.006 · 3.47 Impact Factor